Completed PHASE1 INTERVENTIONAL 4-arm NCT02095587

Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects (IPI-145-14)

A Phase 1, Open-Label, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Duvelisib in Subjects With Chronic Hepatic Impairment Compared to Healthy Subjects

Sponsor: SecuraBio

Conditions Hepatic Impairment

Interventions IPI-145

Updated 8 times since 2017 Last updated: Mar 15, 2021 Started: Mar 31, 2014 Primary completion: Jul 31, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hepatic Impairment and is currently completed. SecuraBio leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Apr 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Apr 2021 [monthly]

Completed PHASE1
Nov 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Nov 2018 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SecuraBio

Data source: SecuraBio

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States